CRIS Current Research Information System

AMABILE, MARILINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.669
EU - Europa 2.024
AS - Asia 1.881
AF - Africa 153
SA - Sud America 89
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.818
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.652
CN - Cina 592
SG - Singapore 522
GB - Regno Unito 502
SE - Svezia 353
VN - Vietnam 332
DE - Germania 271
IT - Italia 241
HK - Hong Kong 123
FR - Francia 107
IN - India 106
UA - Ucraina 103
NL - Olanda 99
RU - Federazione Russa 93
JP - Giappone 91
IE - Irlanda 66
BR - Brasile 63
TG - Togo 56
CI - Costa d'Avorio 40
FI - Finlandia 40
KR - Corea 36
ZA - Sudafrica 34
EE - Estonia 32
CH - Svizzera 31
JO - Giordania 30
BG - Bulgaria 22
BE - Belgio 20
GR - Grecia 17
CA - Canada 15
PL - Polonia 13
AR - Argentina 12
IR - Iran 12
TR - Turchia 10
SC - Seychelles 9
NG - Nigeria 8
BD - Bangladesh 6
PY - Paraguay 5
CL - Cile 4
MY - Malesia 4
AT - Austria 3
EC - Ecuador 3
ES - Italia 3
ID - Indonesia 3
PH - Filippine 3
CZ - Repubblica Ceca 2
IL - Israele 2
KE - Kenya 2
LB - Libano 2
RO - Romania 2
TH - Thailandia 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
CO - Colombia 1
ET - Etiopia 1
IQ - Iraq 1
LT - Lituania 1
MA - Marocco 1
MX - Messico 1
NE - Niger 1
NO - Norvegia 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TN - Tunisia 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.818
Salva come PNG Salva come JPEG
Città #
Southend 443
Singapore 345
Chandler 295
Ashburn 286
Fairfield 269
Woodbridge 141
Dong Ket 138
Houston 136
Wilmington 130
Seattle 129
Hong Kong 121
Hefei 113
Ann Arbor 107
Dallas 103
Beijing 91
Cambridge 90
Princeton 84
Tokyo 81
Jacksonville 71
Dublin 66
Santa Clara 63
Boardman 61
Lomé 56
Nanjing 41
New York 41
Westminster 40
Abidjan 39
Helsinki 39
Padova 37
Turin 36
Seoul 33
Los Angeles 32
Amman 30
Bologna 26
Berlin 25
Bern 25
Ho Chi Minh City 25
Jinan 24
Buffalo 23
Munich 23
Hanoi 22
Milan 21
Saint Petersburg 21
Sofia 21
Brussels 19
Falkenstein 17
Bremen 16
Frankfurt am Main 16
Shenyang 16
San Diego 14
Falls Church 12
Hebei 12
Warsaw 12
Guangzhou 11
Medford 11
Tianjin 11
Washington 11
Bengaluru 10
Haikou 10
Nanchang 10
Taizhou 10
Changsha 9
Dearborn 9
Des Moines 9
Florence 9
Rome 9
Düsseldorf 8
Jiaxing 8
Phoenix 8
Redondo Beach 8
Zhengzhou 8
Hangzhou 7
Istanbul 7
Mahé 7
Mülheim 7
Orem 7
Abeokuta 6
Boston 6
Redmond 6
São Paulo 6
Toronto 6
Xi'an 6
Yubileyny 6
Da Nang 5
Lauterbourg 5
Leawood 5
London 5
Mumbai 5
Norwalk 5
Pune 5
Stockholm 5
Castelfranco Emilia 4
Chengdu 4
Chiyoda-ku 4
Groningen 4
Haiphong 4
Johannesburg 4
Mountain View 4
Olalla 4
Redwood City 4
Totale 4.499
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 313
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 267
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 262
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 255
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 251
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 240
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 232
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 221
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 220
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 204
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 188
Patient-reported outcome measures (PROMs) after elective hip, knee and shoulder arthroplasty: Protocol for a prospective cohort study 181
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 177
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 175
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. 171
Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. 164
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 161
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 159
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 159
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 155
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 151
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 151
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 149
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 146
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 146
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 142
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 137
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia 134
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 132
GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION 129
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients 118
Results of high-dose imatinib mesylate in intermediate SOKAL risk chronic myeloid leukemia patients in early chronic phase: A phase II trial of the GIMEMA CML WP 110
Patient-reported outcomes in patients undergoing elective arthroplasty: the PaRIS-IOR study 106
Overexpression of FBP1 is Associated to High Sokal Risk in Chronic Myeloid Leukemia Patients. 104
New drugs to overcome meccanisms of resistance in Ph+ leukemia: Bosutinib 104
Identifying patient subgroups with different trends of patient-reported outcomes (PROMs) after elective knee arthroplasty 101
Molecular monitoring of acute myeloid leukemia associated with inv(16): Threshold of CBFβ/MYH11 transcript copy number above which relapse occurs and below which continuous complete remission is likely (multiple letters) [8] 97
The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. 93
null 79
null 77
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome 75
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure 71
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. 69
null 57
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC 53
Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia 42
Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia-positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24-homology domains but not the pleckstrin homology one 29
Totale 6.957
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.902
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.902
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021480 0 0 0 0 0 30 4 50 65 37 47 247
2021/2022924 102 13 56 106 79 68 18 52 35 83 160 152
2022/20231.088 125 217 55 140 56 91 36 48 174 20 89 37
2023/2024393 10 49 19 50 29 129 30 27 8 10 20 12
2024/20251.001 30 109 67 87 141 63 75 40 2 133 40 214
2025/20261.167 199 186 305 135 287 55 0 0 0 0 0 0
Totale 6.957